Revlimid (lenalidomide) is a crucial drug for Celgene and its nearly $10 billion in annual revenue is a key part of Bristol-Myers' deal to buy the storied biotech.
Date:2019-03-28 Views:533
Revlimid (lenalidomide) is a crucial drug for Celgene and its nearly $10 billion in annual revenue is a key part of Bristol-Myers' deal to buy the storied biotech.
